Background
This Ruling forms part of a wider piece of work on clinics promoting stem cell therapy for autism in children, identified for investigation following complaints received. See also related rulings published on 23 September 2026.
Ad description
A paid-for Facebook ad for Linden Stem Cell, a stem cell therapy clinic, was seen in February 2026. It included the caption “How can Stem Cell Therapy support children with autism? From reducing inflammation to promoting healing, stem cells offer a new way forward — with real potential for real change […] Swipe to explore how this innovative approach is helping families around the word. #AutismStemCell #LindenStemCell #HopeForHealing #StemCellTherapy #AutismSupport #StemCellTherapy #AutismAwareness #StemCells #LindenClinics […]”.
The ad included a carousel of images. The first image included an image of a young girl and text that stated “HOW DO STEM CELLS WORK FOR AUTISM TREATMENT?”.
The third image included text that stated “How Can Stem Cells Help with Autism? Research suggests that stem cells may help reduce inflammation in the brain and improve communication between cells, which could support positive changes in behaviour and social interaction”.
The fifth image included text that stated “[…] By regenerating damaged cells, they may promote better brain function, helping with skills like focus and social connection”.
The last image included text that stated “[…] Together, let’s explore how stem cells might support your child’s unique needs”.
Below the carousel, the ad displayed the website “LINDENCLINICS.COM”, text that stated “Landing Page Sue Linden Health”, and a button labelled “Learn More”.
Issue
Three complainants challenged whether the claims that stem cell therapy could treat or alleviate traits of autism were misleading and could be substantiated.
Response
Linden Clinics t/a Linden Stem Cell said they did not view or position stem cell procedures as an alternative therapy, and their website clearly stated that such treatment was not a cure for autism and was not a substitute for evidence-based therapies. Their treatment programme included psychological, nutritional and family support, and spanned one year, during which time they encouraged their clients to engage with other medically recommended treatment pathways available to them. They worked with families of autism-diagnosed patients within a multidisciplinary and medically supervised framework. The programme was not designed or presented as a simple commercial treatment pathway, and was not intended to replace established autism support, behavioural therapy, speech therapy, occupational therapy, education, psychological support or nutritional care. The clinical model involved medical pre-assessment, review of existing diagnostic documentation, consideration of patient suitability, exclusion of unsuitable cases, psychological and nutritional support, and continued follow-up over time. Patients were not automatically accepted. Suitably depended on the child’s diagnostic history, neurological history, existing reports, electroencephalogram (EEG) or quantitative electroencephalography (QEEG) findings where relevant, laboratory data, prior clinical records and other medical factors.
They said that autism was a complex neurodevelopmental condition and could not responsibly be approached through a single intervention. Any regenerative medicine-related procedure was positioned only within a wider clinical and supportive framework. Advertising was only the beginning of a longer information and decision-making process. The ad did not lead directly to treatment. Families who contacted Linden Clinics after seeing an ad usually entered a process of medical review, scientific explanation, questioning, family discussion and preparation over a period of months. In many cases, that lasted four to five months and the shortest pathway was usually around three months. The programme was not presented as an alternative to conventional therapy, and it should not be understood as replacing established autism support. The programme included a follow-up after the procedure, for approximately one year.
They did not seek to communicate a guaranteed cure, guaranteed improvement, or guaranteed clinical outcome. They also recognised that the wording should not have implied established efficacy, a standardised outcome applicable to every child, or a direct replacement for conventional autism support. The ad did not claim that stem cell therapy was a treatment that could cure autism. Rather, that stem cell therapy was a potential supportive approach that may help children with autism. The language used was consistently qualified and tentative, and carefully couched in terms of possibility and potential. There was a material distinction between stating that a therapy may assist with certain traits associated with autism and claiming that it was a treatment that could treat or cure the condition.
They said that published literature established that autism was associated with immune dysregulation and neuroinflammation, and the mesenchymal stromal cells possessed immunomodulatory properties. This provided a recognised scientific rationale for investigating whether stem cell therapy may benefit children with autism. They relied on this literature as rational for the qualified, exploratory language used in the ad, and not as proof that stem cell therapy reduced inflammation in the brain in any individual child.
They provided scientific papers to substantiate the claim made in the ad, that stem cell therapy may help support improvement in some traits associated with autism in some children. They also provided a statement from an academic in medical biology and genetics who worked with Linden Clinics and was responsible for the quality of cell production, the standards to which the laboratory operated, the related supply and handling of the cell product, and for explaining the relevant scientific aspects of any procedures to families.
They also provided an internal report looking at outcomes monitored within their programme. As the report was observational, it could not establish causation.
They removed the ad, and prepared an internal action plan for future communications so that they did not describe the pathway as being a guaranteed treatment or cure for autism, and not as a commercial product purchased directly from an ad. Rather, as a clinically supervised, multidisciplinary programme in which regenerative medicine may be considered for selected eligible patients alongside conventional developmental, psychological, behavioural, educational and nutritional support.
Assessment
Upheld
The ad stated “HOW DO STEM CELLS WORK FOR AUTISM TREATMENT? […] How Can Stem Cells Help With Autism? […] Stem cells may work by reducing this inflammation […] By regenerating damaged cells […] let’s explore how stem cells might support your child’s unique needs” and “How can Stem Cell Therapy support children with autism? From reducing inflammation to promoting healing, stem cells offer a new way forward – with real potential for real change […] Swipe to explore how this innovative approach is helping families around the world #AutismStemCell […]”. The ASA considered consumers would understand those claims to mean that stem cell therapy had a physiological effect on the brain and body which could substantially improve the traits associated with autism in children.
The ad also included the claims “Every child is unique, and so is their progress”, “could support positive changes in behaviour and social interaction”, “potentially easing some symptoms”, “they may promote better brain function, helping with skills like focus and social connection”, “Each child’s journey in unique” and “let’s explore how stem cells might support your child’s unique needs”. We considered that whilst those claims indicated that there was some degree of uncertainty about how effective the treatment would be, the overall impression created by the ad was that their stem cell treatment would help, although the extent to which may vary between children, and that the mechanisms by which they improved specific traits were not completely understood.
We therefore expected to see evidence to demonstrate that stem cell treatments had substantially improved the traits associated with autism in children.
We understood from NHS and NICE Guidance that there was no cure for autism, and that stem cell transplants were not a recognised treatment in the UK for autism, including in children.
Notwithstanding that, we noted Linden Clinic’s comment that stem cell therapy was offered as part of a wider treatment programme that included psychological, nutritional and family support. However, because the ad referred only to stem cell therapy, we considered that consumers would understand the claimed benefits to result from that treatment alone, rather than a wider programme. We therefore expected to see evidence demonstrating the efficacy of stem cell therapy in isolation.
We assessed the evidence provided, which included an academic statement, an internal evaluation report, an observational study, a review, three clinical trials, and three systematic reviews.
The academic statement was from a professor and explained that the treatment should not be described as a guaranteed treatment or cure for autism. Notwithstanding that the substance of the statement did not support the ad as consumers would understand it, we did not consider that an academic statement was sufficient to substantiate the ad.
The internal evaluation report, which was provided on a confidential basis, included a retrospective evaluation looking at outcomes of patient records. While we noted that the report stated that it was not presented as clinical trial evidence, we nonetheless considered that the report had not been designed to the same quality as a clinical trial. Notwithstanding that, it was not clear whether the patients included in the report represented all of their patients, and if not, there was no information about how patients had been selected to be included. Furthermore, we understood that the patients included had undergone a multi-disciplinary intervention model and not just stem cell therapy. For those reasons, we considered that the report was not adequate to substantiate the ad.
For the remaining studies, we noted that the types of stem cells used, the methods of administration, treatment protocols, dosing regimens and frequency of treatment varied, and it was unclear how the interventions evaluated corresponded to the treatment offered by Linden Clinic. We considered that those differences limited the extent to which the findings could be applied to the advertised treatment. Nevertheless, we assessed each study individually.
The review looked at existing scientific literature on immune dysfunctions associated with autism, and the potential role for stem cells. We considered that because the study was exploring previous research, and was not an intervention study looking at clinical outcomes of stem cell therapy on improving autism traits in children, the review was not sufficient to substantiate the ad.
The observational study retrospectively looked at 128 children with autism who had undergone stem cell treatment. We considered that because there was no control group, nor were participants or investigators blinded to the intervention, the study was not sufficiently robust to substantiate the ad.
The three clinical trials all involved relatively small numbers of participants, and none demonstrated that they had recruited a sufficient sample size to reliably detect a clinically meaningful treatment effect. We noted that two of the studies included only children within narrow age ranges (three to seven years and three to nine years), which limited the extent to which the findings could be generalised. Furthermore, one trial did not include a control group. While the other two studies included control groups, and one randomly allocated participants to the treatment and control groups, none of the studies concealed the treatment allocation. Consequently, both participants and investigators would have been aware of which participants had received stem cell treatment, increasing the risk of bias. We therefore considered that the studies were not sufficiently robust to substantiate the ad.
The three systematic reviews were largely based on a limited body of heterogeneous studies; many of which involved small sample sizes, lacked appropriate control groups, and evaluated different stem cell types, methods of administration and treatment protocols. We considered that those reviews did not address the methodological limitations we had identified in the underlying evidence, nor did they demonstrate that the findings were applicable to the treatment advertised by Linden Clinic. We therefore considered that they did not provide sufficiently robust evidence to substantiate the ad.
Overall, we considered that the evidence provided was not sufficiently robust to demonstrate that stem cell therapy substantially improved the traits associated with autism in children, or that the treatment offered by Linden Clinic was effective in doing so. We therefore concluded that the claims had not been substantiated and that the ad was misleading.
The ad breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 (Medicines, medical devices, health-related products and beauty products).
Action
The ad must not appear again in the form investigated. We told Linden Clinics t/a Linden Stem Cell not to make claims that stem cell therapy was effective in improving the traits associated with autism in children, unless they held robust evidence to substantiate those claims.
